Key result
Inflammatory biomarkers and Gallium-67 imaging fail to detect histologic subclinical inflammation in chronic RHD.
Why the study?
Persistence of chronic sub-clinical inflammation as a cause of valve disease progression in rheumatic heart disease remains plausible but unproven, and non-invasive identification methods are needed.
Do inflammatory biomarkers and Gallium-67 imaging accurately identify sub-clinical histologic inflammation in patients with chronic rheumatic heart disease?
Cross-Sectional (n=86)
Do inflammatory biomarkers and Gallium-67 imaging accurately identify sub-clinical histologic inflammation in patients with chronic rheumatic heart disease?
Odds Ratio: 3.5 (95% CI 0.68–17.96)
p-value: p=0.133
Conventional inflammatory biomarkers and Gallium-67 imaging are not sufficiently discriminatory to identify sub-clinical histologic inflammation in patients with chronic rheumatic heart disease.
Conventional markers may miss sub-clinical inflammation in chronic RHD; hypothesis-generating for better detection methods.
OBJECTIVE: Valve disease progression in rheumatic heart disease(RHD) is generally attributed to recurrent attacks of acute rheumatic fever(ARF). However, persistence of chronic sub-clinical inflammation remains a plausible but unproven cause. Non-invasive means to identify sub-clinical inflammation may facilitate research efforts towards understanding its contribution to disease progression. METHODS: Patients with chronic RHD, without clinical evidence of ARF, undergoing elective valve surgery were enrolled. Sub-clinical inflammation was ascertained by histological evaluation of left atrial appendage and valve tissue excised during surgery. We assessed the diagnostic utility of Gallium-67 scintigraphy imaging, and inflammatory biomarkers, hsCRP, IL-2, IL-6, Tumor Necrosis Factor-Alpha(TNF-α), Interferon-gamma(IFN-γ), and Serum Amyloid A(SAA), in identifying patients with sub-clinical inflammation. RESULTS: Of the 93 RHD patients enrolled(mean age 34 ± 11 years, 45% females), 86 were included in final analysis. Sub-clinical inflammation was present in 27 patients(31.4%). Patients with dominant regurgitant lesions were more likely to have sub-clinical inflammation compared to those with stenotic lesions, though this association was not statistically significant(dominant regurgitant lesions vs isolated mitral stenosis: OR 3.5, 95%CI 0.68-17.96, p = 0.133). Inflammatory biomarkers were elevated in the majority of patients: hsCRP, IL-2, IL-6, TNF-α, and IFN-γ in 44%, 89%, 90%, 79%, and 81% patients, respectively. However, there was no significant association between biomarker elevation and histologically ascertained sub-clinical inflammation. Ga-67 imaging was unable to identify inflammation in the 15 patients in whom it was performed. CONCLUSION: Sub-clinical inflammation is common in RHD patients. Conventional inflammatory markers are elevated in the majority, but aren't discriminatory enough to identify the presence of histologic inflammation.
No takes yet. Share an insight, caveat, or question.
Singal et al. (2021) conducted a cross-sectional in Chronic rheumatic valvular heart disease (n=86). Dominant regurgitant lesions vs. Isolated mitral stenosis was evaluated on Histologically ascertained sub-clinical inflammation (OR 3.5, 95% CI 0.68-17.96, p=0.133). Conventional inflammatory biomarkers and Gallium-67 imaging were unable to identify histologic sub-clinical inflammation, which was present in 31.4% of patients with chronic rheumatic heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: